SCHEMBL4514356

SCHEMBL4514356

CC(C)(C)c1cc(N)n(-c2cc(O)ccc2Cl)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 5/20 0.40
FGFR1 P11362 4/20 0.40
FGFR2 P21802 4/20 0.40
FGFR4 P22455 4/20 0.40
FGFR3 P22607 4/20 0.40
KDR P35968 4/20 0.40
PRKCZ Q05513 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
ESR1 P03372 1/20 0.37
KDM4E B2RXH2 1/20 0.36
MAPK14 Q16539 4/20 0.35
PDE2A O00408 1/20 0.35
PDE10A Q9Y233 1/20 0.35
ABL1 P00519 1/20 0.35
ABL2 P42684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16280513 0.83 ESR1 (0.37) SRCPRKCZESR1KDM4EMAPK14
SCHEMBL1011502 0.81 MAPK14 (0.43) KDM4EMAPK14ABL1ABL2MAPK8
SCHEMBL29397663 0.81 MAPK14 (0.43) KDM4EMAPK14ABL1ABL2MAPK8
SCHEMBL1283896 0.77 CDK8 (0.47) PRKCZKDM4EMAPK14MAPK11GRN
SCHEMBL4199674 0.77 PRKCZ (0.48) SRCPRKCZKDM4EMAPK14ABL1
SCHEMBL15007938 0.75 GRN (0.43) PRKCZKDM4EMAPK14MAPK11GRN
SCHEMBL13946380 0.75 L3MBTL1 (0.49) PRKCZKDM4EMAPK14ABL1ABL2
SCHEMBL4205964 0.74 PRKCZ (0.57) SRCPRKCZCA1CA2KDM4E
SCHEMBL1409752 0.74 GRN (0.46) SRCMAPK14ABL1ABL2MAPK8
SCHEMBL31265737 0.74 GRN (0.46) SRCMAPK14ABL1ABL2MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3004097-B1 KINASE INHIBITORS CHIESI FARM SPA (IT) 2018-01-17 EP disclosed
EP-3004097-B1 KINASE INHIBITORS CHIESI FARM SPA (IT) 2018-01-17 EP disclosed
US-9440974-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-09-13 US disclosed
US-9440974-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-09-13 US disclosed
US-9440974-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-09-13 US disclosed
EP-3004097-A1 KINASE INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2016-04-13 EP disclosed
US-20160016953-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A (IT) 2016-01-21 US disclosed
US-20160016953-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A (IT) 2016-01-21 US disclosed
US-20160016953-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A (IT) 2016-01-21 US disclosed
US-9181242-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2015-11-10 US disclosed
US-9181242-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2015-11-10 US disclosed
US-9181242-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2015-11-10 US disclosed
US-20140364412-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2014-12-11 US disclosed
US-20140364412-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2014-12-11 US disclosed
US-20140364412-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2014-12-11 US disclosed
WO-2014195402-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2014-12-11 WO disclosed
WO-2014195402-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2014-12-11 WO disclosed
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PFIZER INC. 2009-10-29 US disclosed
EP-1987022-A1 PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES Pfizer Products Inc. (US) 2008-11-05 EP disclosed
WO-2007091176-A1 PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES PFIZER PRODUCTS INC. (US) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160016953-A1 KINASE INHIBITORS MAP3K1, MAP3K2, MAP3K6 SRC 1056/4885FGFR1 785/4885FGFR2 1434/4885
US-20140364412-A1 KINASE INHIBITORS MAP3K1, MAP3K2, MAP3K6 SRC 1056/4885FGFR1 785/4885FGFR2 1434/4885
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PDXK, UMPS, CDK2 SRC 2161/4885FGFR1 2172/4885FGFR2 2137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.